AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
acetylcholine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 65 | 51-84-3 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A neurotransmitter found at neuromuscular junctions, autonomic ganglia, parasympathetic effector junctions, a subset of sympathetic effector junctions, and at many sites in the central nervous system. Miochol-E (acetylcholine chloride intraocular solution) is used to obtain miosis of the iris in seconds after delivery of the lens in cataract surgery, in penetrating keratoplasty, iridectomy and other anterior segment surgery where rapid miosis may be required.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| S (Water solubility) | 100 mg/mL | Bocci G, Oprea TI, Benet LZ |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Bocci G, Oprea TI, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,ACVRL1,AKT2,AKT3,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,ITK,JAK1,JAK2,JAK3,MAP2K6,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPK9,MAPKAPK2,MET,MTOR,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIK3CD,PIK3CG,PIM2,PLK1,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ZAP70 | 58 | |||
| kinase-selectivity-class | ACVR2B,AXL,BRAF,CAMK2D,CDK4,CDK9,DDR1,EPHB4,FLT3,GRK2,MAP3K9,MAPK7,SIK2,STK33,TEK,TTK | 16 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Oct. 9, 1973 | FDA |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | S01EB09 | SENSORY ORGANS OPHTHALMOLOGICALS ANTIGLAUCOMA PREPARATIONS AND MIOTICS Parasympathomimetics |
| FDA MoA | N0000175369 | Cholinergic Agonists |
| CHEBI has role | CHEBI:66981 | ophthalmology drug |
| MeSH PA | D002317 | Cardiovascular Agents |
| MeSH PA | D014665 | Vasodilator Agents |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D018678 | Cholinergic Agents |
| MeSH PA | D018679 | Cholinergic Agonists |
| FDA EPC | N0000175884 | Cholinergic Receptor Agonist |
| CHEBI has role | CHEBI:24621 | hormone |
| CHEBI has role | CHEBI:25512 | neurotransmitter |
| CHEBI has role | CHEBI:35526 | hypoglycemic agent |
| CHEBI has role | CHEBI:35554 | cardiovascular drug |
| CHEBI has role | CHEBI:35620 | vasodilator agent |
| CHEBI has role | CHEBI:38325 | muscarinic agonist |
| CHEBI has role | CHEBI:39456 | antiglaucoma drug |
| CHEBI has role | CHEBI:64946 | anti-HIV agent |
| CHEBI has role | CHEBI:67079 | anti-inflammatory agent |
| CHEBI has role | CHEBI:75771 | mouse metabolite |
| CHEBI has role | CHEBI:75835 | anti-anaemic agent |
| CHEBI has role | CHEBI:77746 | human metabolite |
Related Drugs by ATC class:
S01EB Parasympathomimetics 9 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Glaucoma | indication | 23986001 | DOID:1686 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Muscarinic acetylcholine receptor M3 | GPCR | AGONIST | EC50 | 6.66 | CHEMBL | CHEMBL | |||
| Muscarinic acetylcholine receptor M2 | GPCR | AGONIST | Ki | 6.50 | IUPHAR | ||||
| Muscarinic acetylcholine receptor M4 | GPCR | AGONIST | Ki | 5.60 | IUPHAR | ||||
| Muscarinic acetylcholine receptor M5 | GPCR | EC50 | 6.10 | CHEMBL | |||||
| Neuronal acetylcholine receptor subunit alpha-7 | Ion channel | Ki | 5.10 | CHEMBL | |||||
| Neuronal acetylcholine receptor; alpha4/beta2 | Ion channel | EC50 | 5.80 | CHEMBL | |||||
| Muscarinic acetylcholine receptor M1 | GPCR | EC50 | 6.11 | CHEMBL | |||||
| Acetylcholine-binding protein | Secreted | Ki | 5.50 | CHEMBL | |||||
| Acetylcholine receptor subunit delta | Ion channel | Ki | 7.37 | CHEMBL | |||||
| Neuronal acetylcholine receptor subunit alpha-7 | Ion channel | Ki | 5.45 | CHEMBL | |||||
| Neuronal acetylcholine receptor; alpha2/beta2 | Ion channel | Ki | 7.96 | CHEMBL | |||||
| Neuronal acetylcholine receptor; alpha3/beta2 | Ion channel | Ki | 7.39 | CHEMBL | |||||
| Neuronal acetylcholine receptor; alpha3/beta4 | Ion channel | Ki | 6.21 | CHEMBL | |||||
| Neuronal acetylcholine receptor; alpha4/beta2 | Ion channel | Ki | 8.12 | CHEMBL | |||||
| Neuronal acetylcholine receptor; alpha4/beta4 | Ion channel | Ki | 7.24 | CHEMBL | |||||
| Muscarinic acetylcholine receptor | GPCR | IC50 | 7.92 | CHEMBL | |||||
| Nicotinic acetylcholine receptor alpha8 subunit | Ion channel | EC50 | 4.94 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4019594 | VUID |
| N0000147690 | NUI |
| D00999 | KEGG_DRUG |
| 194 | RXNORM |
| C0001041 | UMLSCUI |
| CHEBI:15355 | CHEBI |
| ACH | PDB_CHEM_ID |
| CHEMBL667 | ChEMBL_ID |
| DB03128 | DRUGBANK_ID |
| CHEMBL1184 | ChEMBL_ID |
| D000109 | MESH_DESCRIPTOR_UI |
| 187 | PUBCHEM_CID |
| 294 | IUPHAR_LIGAND_ID |
| 60-31-1 | SECONDARY_CAS_RN |
| N9YNS0M02X | UNII |
| 4126 | MMSL |
| 72383 | MMSL |
| 438 | INN_ID |
| 4019546 | VANDF |
| 4019594 | VANDF |
| 001697 | NDDF |
| 004684 | NDDF |
| 13525006 | SNOMEDCT_US |
| 387496009 | SNOMEDCT_US |
| 57308006 | SNOMEDCT_US |
| N9YNS0M02X | INXIGHT DRUGS |
Pharmaceutical products:
None